Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.

Pelaia C, Busceti MT, Vatrella A, Rago GF, Crimi C, Terracciano R, Pelaia G.

Pulm Pharmacol Ther. 2019 Jul 22:101830. doi: 10.1016/j.pupt.2019.101830. [Epub ahead of print]

PMID:
31344472
2.

Hexagonal Mesoporous Silica as a Rapid, Efficient and Versatile Tool for MALDI-TOF MS Sample Preparation in Clinical Peptidomics Analysis: A Pilot Study.

Terracciano R, Preianò M, Maggisano G, Pelaia C, Savino R.

Molecules. 2019 Jun 22;24(12). pii: E2311. doi: 10.3390/molecules24122311.

3.

Rapid Detection and Identification of Antimicrobial Peptide Fingerprints of Nasal Fluid by Mesoporous Silica Particles and MALDI-TOF/TOF Mass Spectrometry: From the Analytical Approach to the Diagnostic Applicability in Precision Medicine.

Preianò M, Maggisano G, Murfuni MS, Villella C, Colica C, Fregola A, Pelaia C, Lombardo N, Pelaia G, Savino R, Terracciano R.

Int J Mol Sci. 2018 Dec 12;19(12). pii: E4005. doi: 10.3390/ijms19124005.

4.

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.

Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618810192. doi: 10.1177/1753466618810192. Review.

5.

TLR4 triggered complex inflammation in human pancreatic islets.

He W, Rebello O, Savino R, Terracciano R, Schuster-Klein C, Guardiola B, Maedler K.

Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):86-97. doi: 10.1016/j.bbadis.2018.09.030. Epub 2018 Oct 1.

PMID:
30287405
6.

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.

Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G.

Pulm Pharmacol Ther. 2018 Dec;53:1-5. doi: 10.1016/j.pupt.2018.09.006. Epub 2018 Sep 11.

PMID:
30217438
7.

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.

Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, Terracciano R, Pelaia G.

Biomed Res Int. 2018 May 10;2018:4839230. doi: 10.1155/2018/4839230. eCollection 2018. Review.

8.

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.

Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G.

Drug Des Devel Ther. 2018 Mar 21;12:619-628. doi: 10.2147/DDDT.S155307. eCollection 2018. Review.

9.

An Analytical Method for Assessing Optimal Storage Conditions of Gingival Crevicular Fluid and Disclosing a Peptide Biomarker Signature of Gingivitis by MALDI-TOF MS.

Preianò M, Maggisano G, Murfuni MS, Villella C, Pelaia C, Montalcini T, Lombardo N, Pelaia G, Savino R, Terracciano R.

Proteomics Clin Appl. 2018 Sep;12(5):e1800005. doi: 10.1002/prca.201800005. Epub 2018 Apr 23.

PMID:
29603653
10.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G.

Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017. Review.

11.

Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children.

Pelaia C, Vatrella A, Lombardo N, Terracciano R, Navalesi P, Savino R, Pelaia G.

Expert Opin Biol Ther. 2018 Feb;18(2):197-204. doi: 10.1080/14712598.2018.1402003. Epub 2017 Nov 8. Review.

PMID:
29113525
12.

Objective and self-evaluation voice analysis after transoral laser cordectomy and radiotherapy in T1a-T1b glottic cancer.

Lombardo N, Aragona T, Alsayyad S, Pelaia G, Terracciano R, Savino R.

Lasers Med Sci. 2018 Jan;33(1):141-147. doi: 10.1007/s10103-017-2361-0. Epub 2017 Oct 26.

PMID:
29075995
13.

Dupilumab for the treatment of asthma.

Pelaia C, Vatrella A, Gallelli L, Terracciano R, Navalesi P, Maselli R, Pelaia G.

Expert Opin Biol Ther. 2017 Dec;17(12):1565-1572. doi: 10.1080/14712598.2017.1387245. Epub 2017 Oct 8. Review.

PMID:
28990423
14.

Impact of legumes and plant proteins consumption on cognitive performances in the elderly.

Mazza E, Fava A, Ferro Y, Moraca M, Rotundo S, Colica C, Provenzano F, Terracciano R, Greco M, Foti D, Gulletta E, Russo D, Bosco D, Pujia A, Montalcini T.

J Transl Med. 2017 May 22;15(1):109. doi: 10.1186/s12967-017-1209-5.

15.

A rapid differential display analysis of nasal swab fingerprints to distinguish allergic from non-allergic rhinitis subjects by mesoporous silica particles and MALDI-TOF mass spectrometry.

Lombardo N, Preianò M, Maggisano G, Murfuni MS, Messina L, Pelaia G, Savino R, Terracciano R.

Proteomics. 2017 Mar;17(6). doi: 10.1002/pmic.201600215. Epub 2017 Feb 8.

PMID:
28012241
16.

Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection.

Aiello D, Casadonte F, Terracciano R, Damiano R, Savino R, Sindona G, Napoli A.

Oncoscience. 2016 Jul 8;3(7-8):220-241. doi: 10.18632/oncoscience.313. eCollection 2016.

17.

Role of biologics in severe eosinophilic asthma - focus on reslizumab.

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R.

Ther Clin Risk Manag. 2016 Jul 1;12:1075-82. doi: 10.2147/TCRM.S111862. eCollection 2016. Review.

18.

Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma.

Pelaia G, Vatrella A, Busceti MT, Fabiano F, Terracciano R, Matera MG, Maselli R.

Pulm Pharmacol Ther. 2016 Oct;40:15-21. doi: 10.1016/j.pupt.2016.07.001. Epub 2016 Jul 2. Review.

PMID:
27381656
19.

Influence of storage conditions on MALDI-TOF MS profiling of gingival crevicular fluid: Implications on the role of S100A8 and S100A9 for clinical and proteomic based diagnostic investigations.

Preianò M, Maggisano G, Lombardo N, Montalcini T, Paduano S, Pelaia G, Savino R, Terracciano R.

Proteomics. 2016 Mar;16(6):1033-45. doi: 10.1002/pmic.201500328.

PMID:
26711623
20.

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD.

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R.

Ther Clin Risk Manag. 2015 Oct 8;11:1563-72. doi: 10.2147/TCRM.S84151. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center